



Docket No.: 20142/1201318-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
David Thomas et al.

Application No.: 09/773,866

Confirmation No.: 3286

Filed: February 1, 2001

Art Unit: 1644

For: CD40-BINDING APC-ACTIVATING  
MOLECULES

Examiner: P. Gambel

**AMENDMENT IN RESPONSE TO FINAL OFFICE ACTION**

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed by the U.S. Patent and Trademark Office on July 12, 2005, please enter the following amendments and consider the accompanying remarks. Applicants submit herewith: (i) Exhibit A, ATCC Deposit Receipt; (ii) Exhibit B, information on monoclonal antibody FGK45; (iii) an Amendment Fee Transmittal Sheet, (iv) a Request for Continued Examination (RCE), and (v) an Information Disclosure Statement, with the required fees. It is believed that no additional fees are required. However, the Commissioner is authorized to charge any deficiencies in the required fees and/or to credit any refund owed to our Deposit Account No. 04-0100.

**Amendments to the Specification** are listed on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 6 of this paper.